Another small molecule inhibiting Bcl-2, Bcl-xL and Bcl-w is represented by ABT-737, whose effect on melanoma was demonstrated because of its ability to empower the efficacy of several therapeutic strategies including immunotoxins [129] and BRAF or MEK inhibitor in BRAF-mutated cells [130]. Here, BCL2 is linked to melanoma.